Newsroom

[Forbes.com] The Sovaldi Tax: Gilead Can’t Justify The Price It’s Asking For Hepatitis C Therapy

A cure for hepatitis C is within reach for 170 million people around the world — thanks to the charitable efforts of poor and sick Americans […]

Read more

[The Oregonian] Oregon Health Plan Balk at Hepatitis C Drug Coverage

Eyeing a $168-million annual price tag for two costly new hepatitis C drugs, state officials hope to limit access to a small fraction of the 20,000 […]

Read more

[POLITICO Pro] 80-group campaign targeting hepatitis drug cost

“More than 80 organizations are launching the Campaign for Sustainable Rx Pricing to bring the pharmaceutical company Gilead to the table to negotiate a lower price, […]

Read more

[POLITICO Pulse] NEW COALITION TARGETS SOLVADI COST

“A broad coalition of health care groups is trying to compel the pharmaceutical company Gilead to slim down its profits on the multibillion-dollar hepatitis drug. The […]

Read more